Windtree Therapeutics, Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending June 29, 2020 was $92.8 Million (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) decreased by 0.0%
  • Annual Goodwill and Intangible Assets (Total) for 2019 was $92.8 Million (a 0.0% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of Windtree Therapeutics, Inc.

Most recent Goodwill and Intangible Assets (Total)of WINT including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $92.77 $92.77
2019 $92.77 $92.77 $92.77 $92.77 $92.77
2018 $92.77 $92.77

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.